Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure

Molecular Therapy

Volumn 21, Issue 7, 2013, Pages 1335-1344

  Wang, Xinyi ^a   Ghasri, Pedram ^a   Amir, Mahsa ^a   Hwang, Brian ^a   Hou, Yingpin ^a   Khilili, Michael ^a   Lin, Andrew ^a   Keene, Douglas ^b   Uitto, Jouni ^c   Woodley, David T ^a   Chen, Mei ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 7; CONNECTIVE TISSUE GROWTH FACTOR; RECOMBINANT COLLAGEN TYPE 7; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EPITHELIZATION; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; SKIN INJURY; WOUND CLOSURE; WOUND HEALING;

MURINAE; MUS;

EID: 84879688430     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.87     Document Type: Article

References (46)

1. Gordois, A, Posnett, J, Borris, L, Bossuyt, P, Jönsson, B, Levy, E et al. (2003). The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 1: 2167-2174.
2. Singer, AJ and Clark, RA (1999). Cutaneous wound healing. N Engl J Med 341: 738-746. (Pubitemid 29407375)
3. LeGrand, EK (1998). Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Am J Surg 176(2A Suppl): 48S-54S.
4. Smiell, JM, Wieman, TJ, Steed, DL, Perry, BH, Sampson, AR and Schwab, BH (1999). Effcacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 7: 335-346. (Pubitemid 29523009)
5. Wieman, TJ, Smiell, JM and Su, Y (1998). Effcacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21: 822-827. (Pubitemid 28487079)
6. Lin, AN and Carter, DM (eds) (1992). Epidermolysis Bullosa: Basic and Clinical Aspects. Springer-Verlag: New York.
7. Uitto, J and Christiano, AM (1994). Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res 287: 16-22.
8. Uitto, J and Christiano, AM (1992). Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest 90: 687-692.
9. Parente, MG, Chung, LC, Ryynänen, J, Woodley, DT, Wynn, KC, Bauer, EA et al. (1991). Human type VII collagen: cDNA cloning and chromosomal mapping of the gene. Proc Natl Acad Sci USA 88: 6931-6935. (Pubitemid 21915063)
10. Burgeson, RE (1993). Type VII collagen, anchoring fbrils, and epidermolysis bullosa. J Invest Dermatol 101: 252-255. (Pubitemid 23269892)
11. Sakai, LY, Keene, DR, Morris, NP and Burgeson, RE (1986). Type VII collagen is a major structural component of anchoring fbrils. J Cell Biol 103: 1577-1586. (Pubitemid 17174180)
12. Morris, N P, Keene, DR, Glanville, RW, Bentz, H and Burgeson, RE (1986). The tissue form of type VII collagen is an antiparallel dimer. J Biol Chem 261: 5638-5644. (Pubitemid 17204384)
13. Bruckner-Tuderman, L, Nilssen, O, Zimmermann, DR, Dours-Zimmermann, MT, Kalinke, DU, Gedde-Dahl, T Jr et al. (1995). Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain. J Cell Biol 131: 551-559.
14. Wong, T, Gammon, L, Liu, L, Mellerio, JE, Dopping-Hepenstal, PJ, Pacy, J et al. (2008). Potential of fbroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128: 2179-2189.
15. Wagner, JE, Ishida-Yamamoto, A, McGrath, JA, Hordinsky, M, Keene, DR, Woodley, DT et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363: 629-639.
16. Ortiz-Urda, S, Thyagarajan, B, Keene, DR, Lin, Q, Fang, M, Calos, MP et al. (2002). Stable nonviral genetic correction of inherited human skin disease. Nat Med 8: 1166-1170. (Pubitemid 35175973)
17. Chen, M, Kasahara, N, Keene, DR, Chan, L, Hoeffer, WK, Finlay, D et al. (2002). Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32: 670-675. (Pubitemid 35435183)
18. Woodley, DT, Krueger, GG, Jorgensen, CM, Fairley, JA, Atha, T, Huang, Y et al. (2003). Normal and gene-corrected dystrophic epidermolysis bullosa fbroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121: 1021-1028. (Pubitemid 37430968)
19. Woodley, DT, Keene, DR, Atha, T, Huang, Y, Ram, R, Kasahara, N et al. (2004). Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10: 318-326. (Pubitemid 39117876)
20. Woodley, DT, Keene, DR, Atha, T, Huang, Y, Lipman, K, Li, W et al. (2004). Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10: 693-695. (Pubitemid 38937633)
21. Remington, J, Wang, X, Hou, Y, Zhou, H, Burnett, J, Muirhead, T et al. (2009). Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17: 26-33.
22. Woodley, DT, Remington, J, Huang, Y, Hou, Y, Li, W, Keene, DR et al. (2007). Intravenously injected human fbroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15: 628-635.
23. Woodley, DT, Hou, Y, Martin, S, Li, W and Chen, M (2008). Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis. J Biol Chem 283: 17838-17845.
24. Han, YP, Nien, YD and Garner, WL (2002). Recombinant human platelet-derived growth factor and transforming growth factor-beta mediated contraction of human dermal fbroblast populated lattices is inhibited by Rho/GTPase inhibitor but does not require phosphatidylinositol-3' kinase. Wound Repair Regen 10: 169-176. (Pubitemid 34760895)
25. Woodley, DT, Yamauchi, M, Wynn, KC, Mechanic, G and Briggaman, RA (1991). Collagen telopeptides (cross-linking sites) play a role in collagen gel lattice contraction. J Invest Dermatol 97: 580-585.
26. Akasaka, Y, Ono, I, Tominaga, A, Ishikawa, Y, Ito, K, Suzuki, T et al. (2007). Basic fbroblast growth factor in an artifcial dermis promotes apoptosis and inhibits expression of alpha-smooth muscle actin, leading to reduction of wound contraction. Wound Repair Regen 15: 378-389. (Pubitemid 46817414)
27. Grotendorst, GR, Rahmanie, H and Duncan, MR (2004). Combinatorial signaling pathways determine fbroblast proliferation and myofbroblast differentiation. FASEB J 18: 469-479. (Pubitemid 38326303)
28. Shah, M, Foreman, DM and Ferguson, MW (1995). Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108 (Pt 3): 985-1002.
29. Kim, YH, Woodley, DT, Wynn, KC, Giomi, W and Bauer, EA (1992). Recessive dystrophic epidermolysis bullosa phenotype is preserved in xenografts using SCID mice: development of an experimental in vivo model. J Invest Dermatol 98: 191-197.
30. Heinonen, S, Männikkö, M, Klement, JF, Whitaker-Menezes, D, Murphy, GF and Uitto, J (1999). Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci 112 (Pt 21): 3641-3648.
31. Kern, JS, Loeckermann, S, Fritsch, A, Hausser, I, Roth, W, Magin, TM et al. (2009). Mechanisms of fbroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther 17: 1605-1615.
32. Woodley, DT, Wang, X, Amir, M, Hwang, B, Remington, J, Hou, Y et al. (2013). Intravenously Injected Recombinant Human Type VII Collagen Homes to Skin Wounds and Restores Skin Integrity of Dystrophic Epidermolysis Bullosa. J Invest Dermatol (e-pub ahead of print).
33. Kirfel, G and Herzog, V (2004). Migration of epidermal keratinocytes: mechanisms, regulation, and biological signifcance. Protoplasma 223: 67-78. (Pubitemid 38893461)
34. Li, W, Fan, J, Chen, M and Woodley, DT (2004). Mechanisms of human skin cell motility. Histol Histopathol 19: 1311-1324. (Pubitemid 39386789)
35. Larjava, H, Salo, T, Haapasalmi, K, Kramer, RH and Heino, J (1993). Expression of integrins and basement membrane components by wound keratinocytes. J Clin Invest 92: 1425-1435. (Pubitemid 23273921)
36. Fritsch, A, Loeckermann, S, Kern, JS, Braun, A, Bösl, MR, Bley, TA et al. (2008). A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fbroblast therapy. J Clin Invest 118: 1669-1679. (Pubitemid 351632371)
37. Namazi, MR, Fallahzadeh, MK and Schwartz, RA (2011). Strategies for prevention of scars: what can we learn from fetal skin? Int J Dermatol 50: 85-93.
38. Natarajan, E, Omobono, JD 2nd, Guo, Z, Hopkinson, S, Lazar, AJ, Brenn, T et al. (2006). A keratinocyte hypermotility/growth-arrest response involving laminin 5 and p16INK4A activated in wound healing and senescence. Am J Pathol 168: 1821-1837. (Pubitemid 43825303)
39. Trelford, JD and Trelford-Sauder, M (1979). The amnion in surgery, past and present. Am J Obstet Gynecol 134: 833-845. (Pubitemid 9187958)
40. Uitto, J (2012). Molecular therapeutics for heritable skin diseases. J Invest Dermatol 132(E1): E29-E34.
41. Chen, M, Marinkovich, M P, Veis, A, Cai, X, Rao, CN, O'Toole, EA et al. (1997). Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin. J Biol Chem 272: 14516-14522. (Pubitemid 27251710)
42. Chen, M, Petersen, MJ, Li, HL, Cai, XY, O'Toole, EA and Woodley, DT (1997). Ultraviolet A irradiation upregulates type VII collagen expression in human dermal fbroblasts. J Invest Dermatol 108: 125-128. (Pubitemid 27061020)
43. Sakai, LY, Keene, DR, Morris, NP and Burgeson, RE (1986). Type VII collagen is a major structural component of anchoring fbrils. J Cell Biol 103: 1577-1586. (Pubitemid 17174180)
44. Sakai, LY and Keene, DR (1994). Fibrillin: monomers and microfbrils. In Ruoslahti, E and Engvall, E (eds). Methods in Enzymology, vol. 245. Academic Press: New York. pp. 47-50.
45. van den Dolder, J, Mooren, R, Vloon, AP, Stoelinga, PJ and Jansen, JA (2006). Platelet-rich plasma: quantifcation of growth factor levels and the effect on growth and differentiation of rat bone marrow cells. Tissue Eng 12: 3067-3073. (Pubitemid 44846412)
46. Cheng, CF, Sahu, D, Tsen, F, Zhao, Z, Fan, J, Kim, R et al. (2011). A fragment of secreted Hsp90a carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice. J Clin Invest 121: 4348-4361.